LONDON (ShareCast) - (Sharecast News) - British pharmaceutical company Hikma has inked an exclusive licensing and distribution agreement with Chiesi Farmaceutici, a research-focused business headquartered in Italy.
The agreement will provide Hikma with exclusive rights to commercialise 11 of Chiesi's leading products in Egypt, including currently marketed and pipeline products.

The FTSE 250 firm said the agreement built on its existing partnership with Chiesi in Morocco and added a "range of innovative products" to its Egyptian portfolio.

Hikma vice-chairman Mazen Darwazah said: "This supports our strategy of working with global partners to strengthen our portfolio in growing therapeutic categories.

"In particular, this agreement enables us to meet the needs of a growing number of patients suffering from asthma and COPD in Egypt and improve their access to high-quality medicines."

At 0905 GMT, Hikma shares were up 1.76% at 1,940p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE